Till­man Gern­gross steers a biotech uni­corn to Nas­daq, while an­oth­er com­pa­ny's IPO plans fiz­zle

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The biotech in­dus­try was set to end this week with an­oth­er two ma­jor pub­lic de­buts. The first com­pa­ny, Till­man Gern­gross’ an­ti­body start­up Ada­gio Ther­a­peu­tics, priced a $300 mil­lion-plus IPO on Thurs­day, bring­ing its val­u­a­tion to around $2 bil­lion. But the sec­ond, WCG Clin­i­cal, fell through on its IPO plans, miss­ing out on a po­ten­tial $720 mil­lion raise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.